31st Jan 2022 13:26
31 January 2022
Diurnal Group plc
("Diurnal" or the "Company")
Postponement of R&D Day
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its R&D Day, scheduled to be held on the 2 February 2022, is postponed due to unforeseen personal circumstances. The Company will reschedule the event and will provide further details on the new timings once confirmed.
For further information, please visit www.diurnal.co.uk or contact: | ||
Diurnal Group plc | +44 (0)20 3727 1000 | |
Martin Whitaker, Chief Executive Officer | ||
Richard Bungay, Chief Financial Officer | ||
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0)20 7886 2500 | |
Corporate Finance: Freddy Crossley, Emma Earl | ||
Corporate Broking: Rupert Dearden
| ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
|
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea |
| |
Corporate Broking: Nick Adams |
| |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 | |
Simon Conway | ||
Victoria Foster Mitchell | ||
Alex Davis | ||
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
Related Shares:
DNL.L